Latest Biotech News

Biopharma M&A activity surged in March 2026, with big pharma buyers completing seven transactions worth more than $1 billion each across a 12-day stretch, according to deal tracking summarized in...

Roche escalated its degrader strategy with a new collaboration with C4 Therapeutics focused on degrader-antibody conjugates (DACs), combining C4’s targeted protein degradation payloads with...

Gilead exercised a $45 million option on Kymera Therapeutics’ preclinical molecular-glue degrader program, positioning the company to advance an oral CDK2 degrader into IND-enabling work. Under...

Tempus and Gilead expanded their data partnership, giving Gilead broader access to Tempus’ multimodal real-world cancer datasets and the Tempus AI platform. The update builds on an existing deal...

The FDA denied a petition from Harrison.ai seeking partial exemption from premarket review for certain diagnostic and detection AI devices, provided the manufacturer has 510(k) clearance for a...

Endospan received U.S. premarket approval for its Nexus aortic arch stent graft, bringing the company closer to its planned acquisition by Artivion. The agreement gives Artivion an option to...

Biotech financing activity is rebounding early in 2026, with total biopharma financings reaching $22.82 billion in Q1 2026, up about 74% from $13.12 billion in Q1 2025 but down 31% from the $33.16...

Life Biosciences advanced its clinical epigenetic reprogramming program after raising a fully subscribed $80 million Series D. The funding supports ER-100, which is in phase I trials testing the...

Researchers at the Terasaki Institute for Biomedical Innovation reported a smart polymer contact lens that measures intraocular pressure (IOP) in real time and automatically releases therapy when...

Ibio received key regulatory authorizations in Australia to initiate a first-in-human trial for IBIO-600, its obesity candidate. The Therapeutic Goods Administration (TGA) acknowledged the...

A Nature Communications study mapped how tau species evolve in both plasma and cerebrospinal fluid (CSF) during Alzheimer’s disease progression, providing new “trajectories” for biomarkers rather...

University of Virginia researchers unveiled YuelDesign, YuelPocket and YuelBond, a set of AI tools that use diffusion models to generate drug-like molecules tailored to specific protein...

Gilead exercised an option license on a Kymera Therapeutics protein-degrading program targeting CDK2, while Roche expanded its protein-degrader ambitions via a new collaboration with C4...

The FDA denied a petition from Harrison.ai seeking a partial exemption from premarket review for certain diagnostic/detection AI devices, preserving the existing regulatory status quo. The...

Eli Lilly launched Foundayo, an oral obesity treatment approved by the FDA last week, escalating competition with Novo Nordisk in the oral GLP-1 market. Lilly set the lowest dose at $149 a month...

Tempus announced an expanded, multi-year collaboration with Gilead, giving the pharma access to additional multimodal real-world cancer data and Tempus’s AI platform. The companies previously...

Life Biosciences raised a fully subscribed $80 million Series D to advance ER-100 in phase I trials, targeting biological aging through partial epigenetic reprogramming. The capital funds...

Biopharma financings rebounded strongly in Q1 2026, reaching $22.82 billion, up roughly 74% year over year, according to reported totals. The data show financing activity recovering from a softer...

The FDA issued a warning letter to Medline Inc. over identified issues with its Namic brand angiographic control syringes and manifolds used with radiographic contrast media. The agency said the...

Jeito Capital closed its second fund at $1.2 billion (€1 billion+), targeting 15 to 20 European clinical-stage biopharma companies. The firm said the larger pool allows higher average ticket...